Cantrixil, page-28

I am impressed novogenbuyer - you are correct, more of that posting be good.. I have considered the same thing

However with the lives of many - and much at stake - it is suggested ONC201 is far more advanced in the clinic than Cantrixil. Everybody of course wants progress in this area..... and ONC201 pedigree,  at this stage is ahead of Cantrixil,  I think.  Do you agree ?

-----
Not to waste a chance here - on ONC201 and Oncoceutics...they allocate the drug around the world on compassionate grounds and don't miss the chance to charge and book revenues. They don't miss either - just quietly, on what is charged.. KZA Paxalisib compassionate use and revenue ...I don't know ?

_______________________________________
Note to Management
More use of Paxalisib on compassionate grounds @ cost to patients, please company, would be a great thing.  How about those Overgrowth PROS Spectrum, even a PTEN Group (not previously discussed here) - put the details on on Facebook and distribute around the world. Regulatory approval with the help of Dana Farber (Sure 2 extra full time staff - but make investors, who are part owners of this company proud)  It won't happen though.
____________________________________


This China deal with an undisclosed sale price below - just proceeded  a license deal Oncoceutics entered into for an upfront US$75M., plus milestones and royalties. My rough guess say valued the company today at  US$300M (usual risk discount NPV)

Lets hope ONC201 works with Paxalisb in DIPG........ ONC-201  is limited to H3K27M tumors (DIPG and 10% of all GBM's).....They do talk about its use in other cancers, but it seems to have just been talk in recent year.

So ONC-201 is a tiny portion of the potential use of  Paxalisib (Blood CNS, Brain Mets, GBM & non Cancers)


Oncoceutics Licenses Rights to ONC201 for Greater China to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

• Philadelphia, PA (December 15, 2020) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Greater China to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (“CR Sanjiu”.
  In return for the license and future rights, CR Sanjiu will make a multi-part payment to Oncoceutics including upfront payments, milestone payments, and royalties. CR Sanjiu will also be responsible for the execution of clinical trials required to obtain Marketing Authorization in China and the commercialization of ONC201 in the Chinese market.
  ONC201, the company’s lead development candidate, is a novel small molecule with a unique mechanism of action that has demonstrated anti-cancer activity and safety in several ongoing clinical trials, including clinical trials in adult and pediatric patients with high-grade gliomas. The trials focus on gliomas that harbor a H3 K27M mutation that can be identified by immunohistochemistry or gene sequencing, including the FDA-approved companion diagnostic FoundationOne CDx. H3 K27M-mutant glioma is a molecularly-defined disease with a dismal prognosis. Recently, FDA granted to ONC201: Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, Orphan Drug Designation for the indication of glioblastoma and H3 K27M-mutant glioma, and Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma.
  “